DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Semaglutide is a once-weekly GLP‑1 receptor agonist sold as Wegovy for chronic weight management and Ozempic for type 2 diabetes, plus an oral form (Rybelsus). It mimics the GLP‑1 hormone to curb appetite and slow gastric emptying; in the STEP 1 trial Wegovy produced about 14.9% average weight loss at 68 weeks.
Semaglutide is the same molecule across every brand below — the differences are the FDA-approved indication, dose range, and price. Scored on efficacy, safety, cost, and access.
FDA-approved semaglutide for chronic weight management
Semaglutide approved for type 2 diabetes
Oral semaglutide for type 2 diabetes (FDA-approved 2019)